MedPage Today on MSN1d
Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy
A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
Patient Fatality Forces Reality Check on Sarepta Therapeutics Stock (SRPT)
Sarepta Therapeutics (SRPT) stock is reeling this week following the death of a 16-year-old patient treated with its flagship gene therapy, ...
KTBS 310h
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...
pharmaphorum13h
Sarepta slumps on Elevidys patient death
The tragic death of the 16-year-old boy came as a result of acute liver failure, which is a known side effect of Elevidys and ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare musc ...
Investor's Business Daily on MSN1d
Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.
Sarepta stock crashed Tuesday after a patient who received its approved gene therapy, Elevidys, died due to acute liver failure.
Ticker: Sarepta reports death in drug trial; Google makes $32B cybersecurity deal
Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for ...
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...
StockStory.org on MSN1d
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...